- Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties
-
A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parame
- Christopher, John A.,Aves, Sarah J.,Brown, Jason,Errey, James C.,Klair, Suki S.,Langmead, Christopher J.,Mace, Oliver J.,Mould, Richard,Patel, Jayesh C.,Tehan, Benjamin G.,Zhukov, Andrei,Marshall, Fiona H.,Congreve, Miles
-
supporting information
p. 947 - 955
(2015/05/27)
-
- OREXIN RECEPTOR ANTAGONISTS
-
The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
- -
-
Page/Page column 82-83
(2014/01/18)
-
- Novel piperazine derivatives
-
The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R4, A1, A2 m and n are as described in the specification.
- -
-
-